Skye Bioscience, Inc. (SKYE)
1.79
+0.11
(+6.55%)
USD |
NASDAQ |
Sep 01, 16:00
1.79
0.00 (0.00%)
After-Hours: 20:00
Skye Bioscience Total Long Term Debt (Quarterly) : 0.00 for June 30, 2026
Total Long Term Debt (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Long Term Debt (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.00 |
| March 31, 2026 | 0.00 |
| December 31, 2025 | 0.084M |
| September 30, 2025 | 0.1202M |
| June 30, 2025 | 0.1725M |
| March 31, 2025 | 0.2235M |
| December 31, 2024 | 0.2732M |
| September 30, 2024 | 0.1081M |
| June 30, 2024 | 4.989M |
| March 31, 2024 | 4.760M |
| December 31, 2023 | 4.543M |
| September 30, 2023 | 4.335M |
| June 30, 2023 | 0.2086M |
| March 31, 2023 | 0.00 |
| December 31, 2022 | 1.848M |
| September 30, 2022 | 2.494M |
| June 30, 2022 | 2.445M |
| March 31, 2022 | 2.400M |
| December 31, 2021 | 2.136M |
| September 30, 2021 | 1.921M |
| June 30, 2021 | 1.669M |
| March 31, 2021 | 1.639M |
| December 31, 2020 | 1.498M |
| September 30, 2020 | 1.356M |
| June 30, 2020 | 1.218M |
| Date | Value |
|---|---|
| March 31, 2020 | 0.5178M |
| December 31, 2019 | 0.3871M |
| September 30, 2019 | 3.296M |
| June 30, 2019 | 3.102M |
| March 31, 2019 | 2.914M |
| December 31, 2018 | 1.361M |
| September 30, 2018 | 0.00 |
| June 30, 2018 | 0.00 |
| March 31, 2018 | 0.00 |
| December 31, 2017 | 0.00 |
| September 30, 2017 | 0.00 |
| June 30, 2017 | 0.00 |
| March 31, 2017 | 0.00 |
| December 31, 2016 | 0.00 |
| September 30, 2016 | 0.00 |
| June 30, 2016 | 0.00 |
| March 31, 2016 | 0.00 |
| December 31, 2015 | 0.00 |
| September 30, 2015 | 0.00 |
| June 30, 2015 | 0.00 |
| March 31, 2015 | 0.00 |
| December 31, 2014 | 0.00 |
| September 30, 2014 | 0.00 |
| April 30, 2014 | 0.0354M |
| January 31, 2014 | 0.041M |
Total Long Term Debt Definition
Represents a company's total debt maturing for more than 12 months of the reporting period.
Total Long Term Debt (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Long Term Debt (Quarterly) Benchmarks
| Regeneron Pharmaceuticals, Inc. | 2.707B |
| Viking Therapeutics, Inc. | 3.925M |
| ACADIA Pharmaceuticals, Inc. | 59.55M |
| Alnylam Pharmaceuticals, Inc. | 2.942B |
| Anika Therapeutics, Inc. | 23.32M |